# US 2019/0376031 A1 · Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376031 A1
- Document ID: US20190376031A1
- Status: Published application
- Kind: A1
- Application number: 16/465,773
- Filed: 2017-12-07
- Published: 2019-12-12
- Earliest claimed: 2016-12-07
- Assignees: East Carolina University
- Applicants: East Carolina University
- Inventors: Daniel Stephen WILKINSON; Mark D. MANNIE
- Web page: https://patentgrep.com/patent/US20190376031A1

## CPC

- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/24: Interferons [IFN]
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N 2502/1114: T cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

FOXP3+ regulatory T cells (Tregs) can represent powerful adoptive immunotherapies for autoimmune diseases, metabolic diseases, and other chronic inflammatory diseases. The present invention is related to the ability to maintain and expand stable Treg lines and can provide insight into FOXP3+ Treg physiology and can enable feasible strategies of Treg-based immunotherapy.

## Claims

### Claim 1

A method of preparing a regulatory T-cell (Treg) population comprising:
exposing T-cells to a medium comprising an anti-inflammatory cytokine and an anti-inflammatory cytokine receptor inhibitor; and
propagating the T-cells in the medium comprising the anti-inflammatory cytokine and the anti-inflammatory cytokine receptor inhibitor to provide a Treg population.

### Claim 2 (depends on 1)

The method of claim 1, further comprising, prior to the exposing step,
activating the T-cells to provide activated T-cells, and wherein the exposing step comprises
exposing the activated T-cells to the medium comprising the anti-inflammatory cytokine and the anti-inflammatory cytokine receptor inhibitor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the T-cells are naïve T-cells.

### Claim 4 (depends on 2)

The method of claim 2, wherein the T-cells are activated in the presence of TGF-β and/or IFN-β.

### Claim 5 (depends on 2)

The method of claim 2, wherein the T-cells are activated in the presence of an antigen, a superantigen, and/or a mitogenic stimulus.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the Treg population is an antigen-specific Treg population.

### Claim at position 8

-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the antibody to the anti-inflammatory cytokine receptor and/or antibody fragment thereof is an anti-CD25 antibody and/or a fragment thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the Treg population comprises FOXP3+ Tregs.

### Claim 13 (depends on 1)

The method of claim 1, wherein the Treg population comprises CD4+CD25+FOXP3+ Tregs.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the Treg population comprises Tregs expressing Nrp1 and/or Helios.

### Claim 16 (depends on 1)

The method of claim 1, wherein the concentration of the anti-inflammatory cytokine is in a range of about 1 pM to about 10 nM.

### Claim at position 15

-19. (canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the concentration of the anti-inflammatory cytokine receptor inhibitor is in a range of about 1.0 μg/ml to about 32 μg/ml.

### Claim 21

(canceled)

### Claim 22 (depends on 11)

The method of claim 11, wherein the anti-CD25 antibody binds to a human CD25 epitope homologous to the mouse CD25 epitope recognized by the anti-mouse CD25 monoclonal antibody PC61.

### Claim 23 (depends on 1)

The method of claim 1, wherein the exposing step is performed in vitro.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A Treg population prepared by the method of claim 1.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

A pharmaceutical formulation comprising the Treg population of claim 25, and optionally a pharmaceutically acceptable carrier.

### Claim 28 (depends on 25)

A method of treating, modulating, and/or preventing an immunological disorder in a subject in need thereof comprising a step of administering a therapeutic amount of the Treg population of claim 25 to the subject.

### Claim 29

(canceled)

### Claim 30 (depends on 25)

An adoptive immunotherapy method comprising a step of administering a therapeutic amount of the Treg population of claim 25 to a subject in need thereof.

### Claim at position 27

-38. (canceled)

### Claim 39 (depends on 25)

A method of eliciting a tolerogenic response in a subject in need thereof comprising administering a therapeutic amount of the Treg population of claim 25 to the subject in an amount sufficient to elicit a tolerogenic response.

### Claim at position 29

-45. (canceled)

### Claim 46 (depends on 25)

A method of maintaining a Treg population comprising:
exposing the Treg population of claim 25 to a medium comprising an anti-inflammatory cytokine and an anti-inflammatory cytokine receptor inhibitor; and
maintaining the Treg population in the medium comprising the anti-inflammatory cytokine and the anti-inflammatory cytokine receptor.

### Claim at position 31

-63. (canceled)
